Anne Nagengast Johnson's most recent trade in ATAI Life Sciences N.V. was a trade of 33,545 Common Shares done at an average price of $1.4 . Disclosure was reported to the exchange on March 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.35 per share. | 21 Mar 2025 | 33,545 | 140,045 | - | 1.4 | 45,286 | Common Shares |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 100,000 | 0 | - | - | Restricted Stock Units | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 100,000 | 173,590 | - | - | Common Shares | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 757,915 | 757,915 | - | - | Stock Option | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 326,416 | 326,416 | - | - | Stock Option | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Oct 2024 | 326,416 | 0 | - | - | Stock Option | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 04 Oct 2024 | 115,152 | 0 | - | - | Stock Option | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 115,152 | 115,152 | - | - | Stock Option | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.85 per share. | 02 Apr 2024 | 27,410 | 73,590 | - | 1.9 | 50,709 | Common Shares |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2024 | 550,000 | 550,000 | - | - | Stock Option | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 100,000 | 101,000 | - | - | Common Shares | |
| ATAI Life Sciences NV | Anne Nagengast Johnson | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 100,000 | 100,000 | - | - | Restricted Stock Units |